Bridgeway Capital Management’s Protara Therapeutics TARA Stock Holding History

Bridgeway Capital Management’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$326K	Buy	85,330 +15,000	+21%	+$71.3K	0.01%	963
2026 Q1	$366K	Buy	70,330 +25,500	+57%	+$151K	0.01%	889
2025 Q4	$239K	Hold	44,830	–	–	0.01%	986
2025 Q3	$195K	Sell	44,830 -15,000	-25%	-$48.6K	﹤0.01%	1017
2025 Q2	$181K	Buy	59,830 +19,830	+50%	+$68.4K	﹤0.01%	979
2025 Q1	$170K	Buy	40,000 +15,000	+60%	+$67K	﹤0.01%	952
2024 Q4	$132K	Sell	25,000 -24,200	-49%	-$78.2K	﹤0.01%	1074
2024 Q3	$90K	Buy	49,200 +25,000	+103%	+$51.4K	﹤0.01%	1168
2024 Q2	$50.3K	Sell	24,200 -34,800	-59%	-$102K	﹤0.01%	1220
2024 Q1	$237K	Sell	59,000 -5,000	-8%	-$16.1K	﹤0.01%	1074
2023 Q4	$120K	Hold	64,000	–	–	﹤0.01%	1214
2023 Q3	$107K	Hold	64,000	–	–	﹤0.01%	1220
2023 Q2	$153K	Hold	64,000	–	–	﹤0.01%	1185
2023 Q1	$198K	Hold	64,000	–	–	0.01%	1109
2022 Q4	$172K	Hold	64,000	–	–	﹤0.01%	1119
2022 Q3	$189K	Hold	64,000	–	–	0.01%	1152
2022 Q2	$188K	Hold	64,000	–	–	﹤0.01%	1104
2022 Q1	$327K	Buy	64,000 +10,500	+20%	+$55.2K	0.01%	1048
2021 Q4	$361K	Sell	53,500 -59,000	-52%	-$407K	0.01%	1056
2021 Q3	$779K	Buy	+112,500	New	+$877K	0.01%	901
2017 Q3	–	Sell	-1,180	Closed	-$73K	–	1441
2017 Q2	$73K	Sell	1,180 -295	-20%	-$16.5K	﹤0.01%	1375
2017 Q1	$103K	Hold	1,475	–	–	﹤0.01%	1329
2016 Q4	$112K	Hold	1,475	–	–	﹤0.01%	1355
2016 Q3	$550K	Buy	1,475 +554	+60%	+$195K	0.01%	1051
2016 Q2	$296K	Buy	921 +625	+211%	+$187K	﹤0.01%	1223
2016 Q1	$92K	Hold	296	–	–	﹤0.01%	1381
2015 Q4	$184K	Hold	296	–	–	﹤0.01%	1319
2015 Q3	$165K	Hold	296	–	–	﹤0.01%	1337
2015 Q2	$211K	Buy	+296	New	+$183K	﹤0.01%	1342

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Bridgeway Capital Management's TARA Position: Q2 2026 in Review

Bridgeway Capital Management increased its Protara Therapeutics (TARA) stake by 21% in Q2 2026, buying an estimated $71.3K and bringing the position to 85,330 shares worth $326K. The position accounts for 0.01% of the portfolio, ranked #963.

Bridgeway Capital Management first reported a position in TARA in Q2 2015 and has held it in 29 quarters since. The position peaked at $779K in Q3 2021. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

Bridgeway Capital Management held 85,330 shares of Protara Therapeutics worth $326K as of Q2 2026.
Bridgeway Capital Management bought 15,000 Protara Therapeutics shares in Q2 2026, an estimated $71.3K.
Protara Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #963 holding.
Bridgeway Capital Management first reported a position in Protara Therapeutics in Q2 2015 and has held it in 29 quarters since.
Bridgeway Capital Management's Protara Therapeutics position peaked at $779K in Q3 2021.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.